000 | 01811cam a22004694a 4500 | ||
---|---|---|---|
001 | 15472966 | ||
003 | OSt | ||
005 | 20230220110912.0 | ||
008 | 080925s2008 njua b 001 0 eng c | ||
010 |
_a 2008938265 _z 2008938268 |
||
015 |
_aGBA871787 _2bnb |
||
016 | 7 |
_a101493871 _2DNLM |
|
016 | 7 |
_a014627855 _2Uk |
|
020 | _a1617376948 | ||
035 | _a(OCoLC)ocn166358032 | ||
040 |
_aNLM _cNLM _dUKM _dBTCTA _dBAKER _dYDXCP _dBWX _dLTL _dDLC _dIG# _dDLC |
||
042 | _apcc | ||
050 | 0 | 0 |
_aRC271 _b.G46 2010 |
245 | 0 | 0 |
_aGenomics and pharmacogenomics in anticancer drug development and clinical response / _cedited by Federico Innocenti. |
260 |
_aTotowa, NJ : _bHumana, _c2010 |
||
300 | _axiv, 379p. : | ||
490 | 1 | _aCancer drug discovery and development | |
504 | _aIncludes bibliographical references and index. | ||
505 | 0 | _aGenomic experimental approaches in oncology -- Pharmacogenomics of toxicity and response of chemotherapy -- Pharmacogenomics in clinical drug development in oncology. | |
650 | 0 |
_aCancer _xGenetic aspects. |
|
650 | 0 |
_aCancer _xMolecular aspects. |
|
650 | 0 | _aGenomics. | |
650 | 0 | _aPharmacogenomics. | |
650 | 0 | _aDrug development. | |
650 | 0 |
_aAntineoplastic agents _xDevelopment. |
|
650 | 1 | 2 | _aAntineoplastic Agents. |
650 | 2 | 2 | _aGenomics. |
650 | 2 | 2 |
_aNeoplasms _xdrug therapy. |
650 | 2 | 2 |
_aNeoplasms _xgenetics. |
650 | 2 | 2 |
_aPharmacogenetics _xmethods. |
700 | 1 | _aInnocenti, Federico. | |
830 | 0 | _aCancer drug discovery and development. | |
906 |
_a7 _bcbc _cpccadap _d2 _eepcn _f20 _gy-gencatlg |
||
942 |
_2lcc _cBK |
||
999 |
_c20002 _d20001 |